Hims & Hers Health: Bumpy Ride Will End

Hims & Hers stock has been range-bound due to investor concerns over an FDA letter questioning its compounded GLP-1 marketing, despite the CEO clarifying similar letters were sent industry-wide. While GLP-1s contribute to a targeted $725 million weight-loss segment in 2025, this represents only 31% of the projected $2.35 billion total revenue, as the company emphasizes GLP-1s were never its primary long-term focus. Hims is rapidly diversifying with new offerings in hormonal health, international expansion, and a strategic shift towards a multi-condition membership platform, targeting $6.5 billion in revenue and 10 million subscribers by 2030, suggesting its current valuation at 4x 2026 sales may be discounted given its broader growth trajectory.

Analysis

Hims & Hers Health, Inc. (HIMS) is experiencing a valuation disconnect as the market appears to be overly focused on regulatory scrutiny of its compounded GLP-1 offerings. The stock's recent 6% decline, prompted by an FDA letter, seems disproportionate given that the inquiry is industry-wide and not specific to HIMS. Financially, the weight-loss drug segment, targeted to be a $725 million business in 2025, represents only 31% of the company's projected $2.35 billion revenue for that year, underscoring that GLP-1s are not the core of the investment thesis. While the transition away from commercially available GLP-1s caused a temporary sequential revenue dip of $41 million in Q2, the company projects a swift recovery with Q3 revenue guidance of at least $580 million, signaling a return to growth. The forward-looking strategy is heavily tilted towards diversification and a broader platform play. This includes expansion into hormonal health—a market estimated at 50 million patients—international expansion through the Zava acquisition, and a shift towards a multi-condition personalized subscription model. This subscription segment is already showing significant traction, with subscribers utilizing multi-condition plans growing nearly 170% year-over-year to almost 500,000. With a market cap of $11.5 billion, the stock trades at just 4x its 2026 sales target of $2.8 billion, a multiple that seems modest when compared to its ambitious 2030 targets of $6.5 billion in revenue and a potential subscriber base of 10 million.

Key Decisions for Investors

• Consider the market's negative reaction to the FDA's GLP-1 inquiry as a potential overreaction, as the segment is not the company's primary long-term focus and the regulatory scrutiny is industry-wide.
• Investors should shift focus to the company's rapid diversification and platform strategy, particularly the 170% YoY growth in multi-condition subscribers, which represents the core long-term value driver.
• Monitor the upcoming Q3 revenue results closely; achieving the guided target of at least $580 million will be a critical proof point for the company's resilience and its ability to grow beyond GLP-1 headwinds.
• Evaluate the stock based on its long-term potential as a comprehensive health platform, as its current valuation at 4x projected 2026 sales appears discounted relative to its 2030 revenue and subscriber growth ambitions.